Short answer
MapLight Therapeutics, Inc. (MPLT) filed an 8-K current report with the SEC on May 14, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q1 2026 financial results for quarter ended March 31, 2026.
MapLight Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 with detailed results and management commentary
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation furnished as Exhibit 99.2 for investor, analyst, and other stakeholder meetings
- Presentation available on MapLight Therapeutics’ website
- Reg FD disclosure, not incorporated into SEC filings by reference
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MapLight Therapeutics, Inc. 8-K filings
Get the next MPLT 8-K as it lands
Follow MPLT for push alerts, or ask the research agent what this filing means.